When discontinuing work under a collaborative drug therapy agreement, the Clinical RPh shall notify the board within

When discontinuing work under a collaborative drug therapy agreement, the Clinical RPh shall notify the board within

• A. 5 days
• B. 10 days
• C. 15 days
• D. 30 days

Answer: (B)

When a clinical pharmacist stops working under a collaborative drug therapy agreement, the board expects a prompt notification. This keeps the board’s records accurate and ensures patient care isn’t left in limbo if the collaboration ends. The rule requires reporting within a short, defined window after discontinuation so the board can update its supervisory records and address any ongoing responsibilities for patient safety. Choosing the option that matches this short reporting window aligns with the board’s requirement for timely notification; longer delays would not meet that expectation. This process helps maintain clear oversight of who is authorized to supervise and participate in CDTAs and supports continuity of care for patients.

When a clinical pharmacist stops working under a collaborative drug therapy agreement, the board expects a prompt notification. This keeps the board’s records accurate and ensures patient care isn’t left in limbo if the collaboration ends. The rule requires reporting within a short, defined window after discontinuation so the board can update its supervisory records and address any ongoing responsibilities for patient safety. Choosing the option that matches this short reporting window aligns with the board’s requirement for timely notification; longer delays would not meet that expectation. This process helps maintain clear oversight of who is authorized to supervise and participate in CDTAs and supports continuity of care for patients.